Switch to Icatibant in a Patient Affected by Hereditary Angioedema with High Disease Activity: A Case Report
2012 ◽
Vol 25
(1)
◽
pp. 269-273
Keyword(s):
Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.
2011 ◽
Vol 127
(2)
◽
pp. AB101-AB101
◽
Keyword(s):
Keyword(s):
2008 ◽
Vol 45
(16)
◽
pp. 4118-4119
◽
Keyword(s):
2015 ◽
Vol 135
(2)
◽
pp. AB197
2018 ◽
Vol 141
(2)
◽
pp. AB58
2016 ◽
Vol 26
(1)
◽
pp. 48-72